RG-7410
| Clinical data | |
|---|---|
| Other names | RG7410 |
| Routes of administration | Unspecified[1] |
| Drug class | Trace amine-associated receptor 1 (TAAR1) agonist[1] |
RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.[1][2] Its route of administration was unspecified.[1]
The drug reached phase 1 clinical trials prior to the discontinuation of its development.[1][2] It was under development by Hoffmann-La Roche.[1][2] RG-7410 was first disclosed by January 2014[3] and a phase 1 trial was reported to have been completed by October 2014.[4]
See also
[edit]- Ralmitaront (RG-7906; RO-6889450)
- RG-7351
- Ulotaront (SEP-363856; SEP-856)
References
[edit]- ^ a b c d e f "RG 7410". AdisInsight. 13 October 2015. Retrieved 23 October 2024.
- ^ a b c "Delving into the Latest Updates on RG-7410 with Synapse". Synapse. 19 September 2024. Retrieved 23 October 2024.
- ^ https://assets.roche.com/f/176343/b9882c9bf5/irp140130.pdf
- ^ https://jamesjungkuelee.wordpress.com/wp-content/uploads/2015/01/jpm-2015-roche.pdf
